There is quite a bit of evidence that people are suffering from long covid…memories.
That is to say that few have forgotten the society-crushing hysteria that spread throughout many countries.
So, it was with great trepidation I took a look at reports about United Kingdom researchers who are focused on developing a vaccine for “Disease X.”
On Monday, the term “Disease X” was trending on Twitter or X or whatever the social media platform is called these days. But it didn’t have anything to do with Twitter’s new name or what killed the platform’s previous bird logo.No, the “X” after the word “Disease” was to emphasize that it’s not known which virus or other pathogen may be the next to jump from other animals to humans to become a threat and maybe even cause a pandemic.This X marks one of the spots as to why the U.K. is establishing the Vaccine Development and Evaluation Centre (VDEC), situated at the U.K. Health and Security Agency (UKHSA) Porton Down campus in Wiltshire. As an August 7 announcement from the UKHSA indicated, “Working with national and international partners, VDEC’s skills and resources will enable the development of the vaccines we urgently need to save lives and mitigate the harm from vaccine preventable disease.This includes threats from known and new pathogens, including viruses of pandemic potential.” In other words, this is an attempt to stack the VDEC against future emerging pathogens that may try to wreak havoc amongst humanity.
Why does the vaccine have to be the de facto solution for diseases? There are also options for early treatment development, the creation of novel disinfecting agents, and encouraging people to get fit and eat healthy.
British researchers apparently have over 100 different projects going. The pathogens they are looking at include tuberculosis and monkeypox, which we have covered extensively at Legal Insurrection.
…More than 200 scientists are working on upwards of 100 projects at the top secret laboratory in Porton Down, run by the UK Government.These include surveillance and potential vaccine development for diseases including tuberculosis and monkeypox.Top scientists working at the site however today confirmed they are readying the tools that would be needed if the H5N1 bird flu strain took off in humans.The biggest ever outbreak of avian influenza is currently sweeping the world, sparking fears it could soon jump to humans.While it is not known to transmit easily between humans, mutations to the virus that makes mammal-to-mammal transmission easier could change that, some experts fear.Earlier this year British scientists also modeled worst-case scenarios under which the virus kills up to one in 20 people it infects, if it ever manages to take off in humans.
The researchers have already begun human testing of a vaccine for one of the hemorrhagic fevers.
One early success is the world’s first vaccine against Crimean-Congo haemorrhagic fever, a disease that’s spread by ticks and has a fatality rate of 30%.Early-stage clinical trials have just started, with 24 volunteers expected to test the jab.The disease is becoming more common in Europe as global temperatures rise and some travellers have returned to the UK with the infection.
“Climate Change” is part of the justification for this approach.
The combination of climate change, urbanisation and people living closer to animals – the source of many new diseases which transfer to people – means we’re facing a “rising tide of risk”, [Prof Dame Jenny Harries, chief executive of the UK Health Security Agency (UKHSA)] says.
Just because vaccines are built doesn’t mean a new distrustful public will use them.
Germany’s BioNTech (22UAy.DE), Pfizer’s (PFE.N) partner on COVID-19 vaccines, cut its drug development budget for this year after quarterly revenues were hurt by a plunge in pandemic-related demand.Second-quarter revenue dropped to 167.7 million euros ($184 million) from 3.2 billion euros a year earlier, as write-offs on Pfizer’s assets ate into profit share payments that BioNTech is entitled to receive from its U.S. partner.The quarterly net loss was 190 million euros, down from a COVID-19-fuelled profit of 1.67 billion euros a year earlier.”With some uncertainty on the revenue line, we are also carefully watching our spending by revisiting our cost base,” said finance chief Jens Holstein, adding that BioNTech’s ambition to become a multi-product oncology and infectious disease company was unchanged.
Who knows…maybe we will actually get lucky, and one of the novel vaccines will actually stop transmission. Maybe even without affecting heart enzymes.
CLICK HERE FOR FULL VERSION OF THIS STORY